Agency Business briefs

Share this article:
Novartis awarded professional advertising accounts for Gleevec and Tasigna to Harrison & Star following a five-way pitch, pitting it against Saatchi & Saatchi Healthcare, Euro RSCG Life, Torre Lazur McCann and incumbent AgencyRx.

Partners + simons relaunched its website, partnersandsimons.com, with a more user-friendly feel aimed at showcasing the company's online capabilities and includes a “long scroll” approach so users don't have to click around.

LehmanMillet won accounts with Myriad Genetics, which retained the shop for its BRACAnalysis breast and ovarian cancer diagnostic, and Breathe Technologies, which is developing a franchise of compact, ultra-lightweight ambulatory respirator systems. The shop is part of the HealthSTAR Communications network.

Cadient Interactive launched Hatch Consulting, an interactive marketing consultancy. The unit will offer clients expertise in market development, mobile marketing, consumer relationship marketing, social and emerging media, program optimization and analysis, customer acquisition, user experience, creative execution and research insights. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?